chronic obstructive pulmonary disease
Conditions
Interventions
1:salmeterol / fluticasone propionate 50/500ug Bid for 12 weeks
Sponsors
The Second Affiliated Hospital of the Third Military Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1. Outpatients; aged between 40 and 79 years old, male or female; 2. With diagnosis of moderate to severe COPD: After the use of bronchodilator agents, FEV1/FVC=10 years); 4. Have not used the drugs prohibited in this trial within 30 days of enrollment (with stable dosage); 5. Patients that can properly use the diskus and medication; 6. Sign the informed consent forms.
Exclusion criteria
Exclusion criteria: 1. With other severe diseases that might cause potential risks in patients participating in the trial, influence the outcomes of the trial or affect the ability of patients to take part in the trial; 2. Comorbidity with other diseases of respiratory system (ie. asthma); 3. Patients that need regular or long-term oxygen therapy (>12 hours per day); 4. Patients treated with inhalation or systemic glucocorticoids or/and long-term beta 2 agonists and/or anti-cholinergic drugs; 5. Episodes of moderate to severe AECOPD within 30 days of enrollment (exacerbation of COPD and with the need of systemic glucocorticoids and/or antibiotics therapy or hospitalization); 6. Episodes of respiratory tract infection that need antibiotics therapy within 14 days of enrollment; 7. Use of certain inhibitors (ie. beta receptor blocker); 8. Pregnant or breast-feeding females (* women of reproductive age should adopt contraceptive methods).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of CD4+CD25+ FoxP3+ regulatory T cells in CD4+ T cell; | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-8, TNF-alpha, IL-10 AND 1L-17A in induced sputum;Serum IL-8, TNF-alpha, IL-10 AND 1L-17A;Cells counts in induced sputum; | — |
Countries
China
Contacts
Public ContactGuansong WANG
Outcome results
None listed